We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Heron Therapeutics Inc (HRTX) USD0.01

Sell:$1.71 Buy:$1.72 Change: $0.08 (4.88%)
Market closed |  Prices as at close on 5 December 2024 | Switch to live prices |
Sell:$1.71
Buy:$1.72
Change: $0.08 (4.88%)
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now
Market closed |  Prices as at close on 5 December 2024 | Switch to live prices |
Sell:$1.71
Buy:$1.72
Change: $0.08 (4.88%)
Market closed |  Prices as at close on 5 December 2024 | Switch to live prices |
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Heron Therapeutics, Inc. is a commercial-stage biotechnology company. The Company commercializes a portfolio of products to care for acute care and oncology patients. Its oncology care product portfolio includes SUSTOL and CINVANTI. SUSTOL is used for the prevention of acute and delayed nausea and vomiting associated with both moderately emetogenic chemotherapy (MEC), and anthracycline and cyclophosphamide (AC) combination chemotherapy regimens. CINVANTI is an intravenous (IV) formulation of aprepitant, a substance P/neurokinin-1 (NK1) receptor antagonist. Its acute care product portfolio includes ZYNRELEF and APONVIE. HTX- ZYNRELEF is a dual-acting local anesthetic that delivers a fixed-dose combination of the local anesthetic bupivacaine and a low dose of the nonsteroidal anti-inflammatory drug meloxicam. APONVIE is the IV formulation of a NK1 receptor antagonist indicated for postoperative nausea and vomiting (PONV). Its products are distributed in the United States.

Contact details

Address:
4242 Campus Point Court, Suite 200
SAN DIEGO
92121
United States
Telephone:
+1 (858) 2514400
Website:
https://www.herontx.com/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
HRTX
ISIN:
US4277461020
Market cap:
$179.47 million
Shares in issue:
152.09 million
Sector:
Biotechnology
Exchange:
NASDAQ
Country:
United States
Currency:
US dollar
Indices:
n/a

Key personnel

  • Adam Morgan
    Chairman of the Board
  • Craig Collard
    Chief Executive Officer, Director
  • Ira Duarte
    Chief Financial Officer, Principal Accounting Officer
  • William Forbes
    Executive Vice President, Chief Development Officer
  • Lisa Peraza
    Vice President

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.

Options

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.